Insider Weekends: CEO Of Medpace Purchases Over $4 Million Worth Of Stock

Clinical Research Organizations or CROs have become a critical partner for biotech and pharma companies large and small. CROs help these companies during phases I to IV of the drug development process and the suite of services they offer often extend well beyond just patient recruitment for drug studies. Medpace Holding (MEDP) is a CRO that focuses on small and mid-size biotechs and is one of the smaller CROs compared to companies like ICON (ICLR), IQIVIA (IQV) and Charles River Laboratories (CRL) that work with the big pharmaceutical companies and are several times larger than Medpace (MEDP). Biotech stocks have been in a world of pain long before the tech bubble burst late last year and the big drop in stock prices combined with a more challenging funding environment this year has dampened investor enthusiasm for companies like Medpace Holdings with the stock down nearly 25% this year. Despite this challenging environment, the company managed to grow revenue 24% last year and the pace of growth accelerated in Q1 2022 with revenue increasing 27.3% to $331 million. The company’s backlog of business is probably helping the company at the moment and growth is expected to taper next year. The company...

Only plus or premium subscribers can access this post. Subscribe today.

Leave A Comment

You must be logged in to post a comment.